表紙
市場調查報告書

子宮肌瘤(Uterine leiomyoma) - 開發平台分析

Arrhythmias - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 234336
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
子宮肌瘤(Uterine leiomyoma) - 開發平台分析 Arrhythmias - Pipeline Review, H2 2019
出版日期: 2019年11月29日內容資訊: 英文 84 Pages
簡介

子宮肌瘤是發生在子宮的良性腫瘤。雖然肌瘤和子宮壁(子宮平滑肌)一樣是平滑纖維,但卻較正常子宮肌層更厚,一般呈球型腫塊。子宮肌瘤最常見的症狀有嚴重的月經出血,月經持續七天以上,骨盤壓或疼痛、頻尿、排尿障礙、便秘及背部疼痛和下肢痛等。

本報告提供子宮肌瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等,以及最新的新聞和發表等資訊。

簡介

  • 調查範圍

子宮肌瘤概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發企業

  • Euroscreen S.A.
  • Takeda Pharmaceutical Company Limited
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Kissei Pharmaceutical Co., Ltd.
  • Bayer AG
  • BioSpecifics Technologies Corp.
  • Repros Therapeutics Inc.
  • Dongkook Pharmaceutical Co., Ltd.
  • HRA Pharma
  • AbbVie Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ulipristal acetate
  • relugolix
  • elagolix sodium
  • telapristone acetate
  • mifepristone
  • KLH-2109
  • vilaprisan
  • ESN-364
  • LFA-102
  • collagenase clostridium histolyticum
  • GnRH Antagonists
  • EVE-104
  • triptorelin pamoate biosimilar
  • Drug to Activate Progesterone Receptor for Uterine Fibroids
  • Drugs for Women Health

最近的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11861IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H2 2019, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arrhythmias - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 11 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Arrhythmias - Overview
  • Arrhythmias - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Arrhythmias - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Arrhythmias - Companies Involved in Therapeutics Development
  • Aetas Pharma Co Ltd
  • Armgo Pharma Inc
  • BlueRock Therapeutics
  • Cardurion Pharmaceuticals LLC
  • Cynata Therapeutics Ltd
  • Espero BioPharma Inc
  • Galectin Therapeutics Inc
  • Gilead Sciences Inc
  • LATITUDE Pharmaceuticals Inc
  • Les Laboratoires Servier SAS
  • LQT Therapeutics Inc
  • OMEICOS Therapeutics GmbH
  • Orion Corp
  • SignPath Pharma Inc
  • Trucode Gene Repair Inc
  • Arrhythmias - Drug Profiles
  • amiodarone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antisense Oligonucleotides to Activate hERG1 for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • belapectin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CYP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • efsevin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ESP-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GS-680 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GS-967 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KN-93 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • M-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MC-450 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oligonucleotides to Activate KCNH2 for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OMT-28 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ORM-10103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PP-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules 1 for Arrhythmia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Arrhythmia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RyR2 for Heart Failure and Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Block KCa3.1 for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules To Inhibit SGK-1 for Long QT Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SPP-4040 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Arrhythmias - Dormant Projects
  • Arrhythmias - Discontinued Products
  • Arrhythmias - Product Development Milestones
  • Featured News & Press Releases
  • Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology
  • Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
  • Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Arrhythmias, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Arrhythmias - Pipeline by Aetas Pharma Co Ltd, H2 2019
  • Arrhythmias - Pipeline by Armgo Pharma Inc, H2 2019
  • Arrhythmias - Pipeline by BlueRock Therapeutics, H2 2019
  • Arrhythmias - Pipeline by Cardurion Pharmaceuticals LLC, H2 2019
  • Arrhythmias - Pipeline by Cynata Therapeutics Ltd, H2 2019
  • Arrhythmias - Pipeline by Espero BioPharma Inc, H2 2019
  • Arrhythmias - Pipeline by Galectin Therapeutics Inc, H2 2019
  • Arrhythmias - Pipeline by Gilead Sciences Inc, H2 2019
  • Arrhythmias - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2019
  • Arrhythmias - Pipeline by Les Laboratoires Servier SAS, H2 2019
  • Arrhythmias - Pipeline by LQT Therapeutics Inc, H2 2019
  • Arrhythmias - Pipeline by OMEICOS Therapeutics GmbH, H2 2019
  • Arrhythmias - Pipeline by Orion Corp, H2 2019
  • Arrhythmias - Pipeline by SignPath Pharma Inc, H2 2019
  • Arrhythmias - Pipeline by Trucode Gene Repair Inc, H2 2019
  • Arrhythmias - Dormant Projects, H2 2019
  • Arrhythmias - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Arrhythmias - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Arrhythmias, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top